Short answer
Edwards Lifesciences (EW) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.7B (up 10.5% year over year) with net income of $308M.
Q3 2026 key financials · XBRL
- Revenue
- $1.7B
- +10.5% YoY · −1.5% QoQ
- Net income
- $308M
- +5.6% YoY · +27.1% QoQ
- Operating margin
- 17.4%
- Gross margin
- 78.5%
- EPS (diluted)
- $0.54
- +10.2% YoY · +31.7% QoQ
Source: XBRL data from the Edwards Lifesciences (EW) Q3 2026 10-Q on SEC EDGAR. USD.
Edwards Lifesciences Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $1,715.5M, up 10.5% YoY from $1,553.1M
- TMTT best-performing segment: $209.5M, up 44.3% YoY; Surgical lowest growth at 2.5%
- Effective tax rate 17.0% vs 16.1% YoY; impairment charges $220.2M
- Operating cash flow $1,266.0M, up $121.7M; share repurchases $714.0M
- Tariffs pose potential demand and cost headwinds; 2026 Pillar Two tax expense expected at approximately $45.0M
Risk Factors
- No material changes to risk factors reported since the December 31, 2025 Form 10-K
- Carried-forward risks remain governed by the 2025 Annual Report’s Risk Factors section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edwards Lifesciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.